Wall Street equity research analysts tracking Corcept Therapeutics maintain a favorable consensus rating, leaning strongly toward a buy or outperform recommendation. Financial experts point to robust commercial revenue generation, expanding market penetration for Cushing's syndrome treatments, and promising clinical catalysts as strong justifications for maintaining a positive investment thesis on the stock.